#3-Smiley Riley(#698510) -From your link (thank you)
"So
#3-Smiley Riley(#698510) -From your link (thank you)
"So critical care patients can get eIND's if they aren't at one of the clinical trial sites. All the doctors in the current sites should get their patients enrolled ASAP. What makes this announcement so powerful is that the doctors in this study were blinded. They thought it was working but after they enroll a couple of patients they will know it is working and this word will spread like wild fire. I expect patient recruitment to go through the roof next week.
"This impending EUA / outright approval is long overdue. With over 100 miraculous EIND stories, 5 trials for Mild/Moderate & Severe Critical, 2 publications, countless 'ambassadors of Leronlimab or Vyrologix its brand name including the likes of Dr Bruce Patterson among many others.
"To anyone with a loved one in the hospital with Covid19 or suffering from Covid Longhaulers symptoms I highly suggest asking your doctor for this incredible monoclonal antibody treatment. This therapy targets the CCR5 cell and reduces the viral load in days! I strongly believe it should have gotten approval by NIH, OWS and FDA many months ago as it concluded MM trials in May.
Not going to get into political corruption theory here but Big Pharma came first w 3 drugs that don't work. Read into it what you will. Many stories will be written about this in the months to come. God only knows how many lives could have been saved had Leronlimab been allowed to go to market back in June...just around the time that Gileads Remdesivir trumped over CytoDyns Leronlimab....hmm, very odd eh. Remdesivir was ruled by OWS as ineffective for those unaware.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Top 5 Most Recently Viewed Articles
Introduction to Click Fraud in EMEA In the digital age, understanding the landscape of click fraud has become crucial for businesses engaging in online advertising. Recent findings have illuminated the extent of click fraud in the EMEA region, showcasing significant statistics that could impact advertisers and digital marketers alike. This article delves into the insights...
Continue Reading
EPR Properties Reports Strong Third Quarter Results EPR Properties (NYSE:EPR) has recently released its operating results for the third quarter. The data highlighted a promising performance across various metrics, indicating effective management strategies and a strong investment pipeline. Financial Overview For the third quarter, EPR Properties reported total revenue of...
Continue Reading
Understanding the Current Options Trading Landscape for Impinj In recent times, it seems that major investors are adopting a cautious stance towards Impinj (NASDAQ: PI). It is important for those involved in the market to pay attention to this shift. Observations of the public options markets reveal some notable movements that might indicate potential developments around...
Continue Reading
Snap-On Holds Steady Amid Mixed Quarter Results Baird has recently reaffirmed a Neutral rating on Snap-On (NYSE: SNA) while raising the price target to $290, an increase from the previous $275. This change in outlook follows Snap-On's second quarter performance, which revealed a blend of outcomes across different segments. During this quarter, Snap-On encountered...
Continue Reading
Drone Technology Revolutionizes Industrial Surveying The drone surveying market is rapidly evolving, driven by an increasing demand for aerial intelligence and precise mapping across various sectors including agriculture, construction, mining, and environmental monitoring. These advancements allow businesses to enhance operations and make crucial real-time decisions using...
Continue Reading